Value Adjusted for Debt and Cash: Quoin Pharmaceuticals Ltd. (QNRX)

Quoin Pharmaceuticals (QNRX) focuses on developing therapies for rare dermatological pathologies, leveraging FDA orphan drug status and clinical trial successes for Netherton syndrome. The company implements ESG standards in its research by reducing toxic waste and adhering to bioethics. Its human capital is based on a tight-knit circle of experts whose loyalty is maintained through stock options. The current enterprise value stands at -1.67, as clearly illustrated by the valuation chart.

Enterprise value combines market capitalization with net debt, determining the actual cost of a full business buyout inclusive of all liabilities. For Quoin Pharmaceuticals (QNRX), which relies on external contractors for manufacturing and clinical trials, the enterprise value reflects the real price of control over intellectual property in the absence of proprietary assets.